Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | GAPDH | P04406 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9282371 | 0.85 | HPGD (0.62) | HPGDALDH1A1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL10344961 | 0.82 | HPGD (0.68) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL8195491 | 0.81 | USP2 (0.51) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL9185531 | 0.81 | HPGD (0.66) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL5495002 | 0.81 | HPGD (0.66) | HPGDALDH1A1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12264637 | 0.81 | HPGD (0.66) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL11585107 | 0.81 | HPGD (0.66) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL8316469 | 0.81 | HPGD (0.66) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL10345060 | 0.80 | HPGD (0.60) | HPGDALDH1A1RAB9AMAPK8POLB | |
| SCHEMBL12057484 | 0.80 | POLB (0.60) | HPGDALDH1A1RAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3186238-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1379240-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-0918748-B1 | FUNGICIDES | ZENECA LTD (GB) | 2000-12-20 | — | — | EP | disclosed |
| US-6124356-A | Fungicides | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| EP-0918748-A1 | FUNGICIDES | ZENECA LIMITED (GB) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998004520-A1 | FUNGICIDES | ZENECA LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| US-4788194-A | CARDIOTONIC AGENTS, HYPOTENSIVE AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-11-29 | — | — | US | disclosed |
| US-4716164-A | CARDIOTONIC, HYPOTENSIVE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-29 | — | — | US | disclosed |
| US-4558045-A | CARDIOTONIC AND HYPOTENSIVE ACTIVITY | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-12-10 | — | — | US | disclosed |
| US-4489073-A | HYPOTENSIVE AND CARDIOTONIC AGENTS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1984-12-18 | — | — | US | disclosed |
| US-4399075-A | Process for producing chlorinated phenoxytoluene derivatives | ASAHI CHEMICAL COMPANY, LIMITED (JP) | 1983-08-16 | — | — | US | disclosed |
| EP-0085227-A1 | Thiadiazine derivatives, and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | HPGD 1538/4885ALDH1A1 2955/4885RAB9A 2668/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | HPGD 2166/4885ALDH1A1 2364/4885RAB9A 1103/4885 |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | HPGD 875/4885ALDH1A1 802/4885RAB9A 758/4885 |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, APLNR | HPGD 2166/4885ALDH1A1 2364/4885RAB9A 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.